SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
- Written by PR Newswire
 |
- Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant
- Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market
- "Our SKYCellflu platform with our adjuvanted vaccine experience will lay a strong foundation for future...
